A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Inclusion Criteria:

• Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal cancer, or squamous cell cancer of the head and neck
• Have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines (except prostate cancer patients)
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
• Are willing to follow study procedures for the duration of the study
• Are willing to use an approved contraceptive method during treatment and for 3 months after discontinuation of study treatment

Exclusion Criteria:

• Have a serious preexisting medical condition that would preclude participation in the study
• Are pregnant or lactating
• Have received treatment within 28 days of first dose of LY2523355 with a drug that has not received regulatory approval for any indication
• Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases
• Have a second active primary malignancy or a history of a second malignancy requiring cytotoxic therapy
• Have QTc interval greater than 470 msec or intraventricular conduction delay (IVCD) with QRS greater than 120 msec on screening electrocardiogram (ECG)
• Have active symptomatic fungal, bacterial, and/or known viral infection including active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis
• Patients with pneumonia, evidence of obstructive pneumonitis, other respiratory infections, or infection from other sources are to be excluded